|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The possible explanation is that the two drugs can reduce the expression of sPLA2-V in myocardium and aortic trunk, which in turn relieved atherosclerosis and achieved better therapeutic effect.
|
30402154 |
2018 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Secretory phospholipases (sPLA2) are a group of pro-inflammatory molecules associated with diseases such as atherosclerosis, which increase the risk of reperfusion injury.
|
28525795 |
2017 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Secretory phospholipase A2 (sPLA2) enzymes are considered to play a role in atherosclerosis. sPLA2 activity encompasses several sPLA2 isoenzymes, including sPLA2-V.
|
24563418 |
2014 |
|
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Secretory phospholipases (sPLA2) are associated with inflammation, hyperlipidemia and atherosclerosis.
|
24440706 |
2014 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Secretory phospholipase A2 (sPLA2) enzymes are thought to contribute to atherosclerosis.
|
23880195 |
2013 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PLA2G10 expression in bone marrow cells controls a proatherogenic Th1 response and limits the development of atherosclerosis.
|
23349189 |
2013 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The family of secretory phospholipase A2 (sPLA2) enzymes has been associated with inflammatory diseases and tissue injury including atherosclerosis.
|
19129734 |
2009 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To understand the cellular changes associated with the progress of atherosclerosis, we evaluated the role of sPLA(2)-IIA in mediating monocyte recruitment and differentiation into antigen-presenting cells.
|
18755682 |
2009 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bone marrow transplantation to LDL receptor-deficient mice was performed to study sPLA2 IIa in atherosclerosis.
|
15576846 |
2005 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The abundant secretion of type IIA secreted phospholipase A(2) (sPLA(2)) is a major feature of the inflammatory process of atherosclerosis. sPLA(2) is crucial for the development of inflammation, as it catalyses the production of lipid mediators and induces the proliferation of smooth muscle cells.
|
12188923 |
2002 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, arterial specimens obtained at autopsy after sudden death were analyzed concerning (1) the presence of Chlamydia pneumoniae, cytomegalovirus, herpes simplex virus, and Helicobacter pylori; (2) the expression of secretory group IIA phospholipase A(2) (sPLA(2)-IIA) and of proinflammatory cytokines; and (3) the stage of atherosclerosis.
|
10712401 |
2000 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The current study was undertaken to determine whether 1 mechanism by which group II sPLA2 might contribute to the progression of inflammation and atherosclerosis is by increasing the formation of biologically active oxidized phospholipids.
|
10323782 |
1999 |